53 F
Fort Worth
Tuesday, December 1, 2020
Energy House bill would speed drug approvals, boost research

House bill would speed drug approvals, boost research

Other News

Closing prices for crude oil, gold and other commodities

The Associated Press Benchmark U.S. crude oil for September delivery rose 31 cents to settle at $41.60 a barrel Monday. Brent crude oil for...

Trump to discuss energy, tour oil rig, raise money in Texas

By DARLENE SUPERVILLE Associated PressWASHINGTON (AP) — President Donald Trump will shift his focus to American energy dominance during a stop in Texas later...

Basic Energy Services makes organizational changes

Fort Worth-based Basic Energy Services, Inc. (OTCQX: BASX) in late May announced the implementation of changes to the organizational structure of the company, reducing...

Texas oil producers were cutting output before Railroad Commission chose not to, Commissioner Christi Craddick says

By Cassandra PollockMay 12, 2020 Texas Railroad Commissioner Christi Craddick on Tuesday doubled down on the agency’s recent decision to not cut oil production and...

WASHINGTON (AP) — Urged on by the medical industry and patients’ groups, the House overwhelmingly approved a bipartisan bill that would speed federal approval of drugs and medical devices and boost biomedical research.

The measure’s easy 344-77 passage on Friday came despite objections from consumer organizations and others arguing the measure would erode government safeguards against dangerous and ineffective products.

The bill’s supporters said that with advances like genetic mapping and biologic medicines produced in living cells, it is time to streamline how federal regulators assess the safety of new treatments and let them reach markets.

“We have a chance to do something big, and this is our time,” said Rep. Fred Upton, R-Mich., chairman of the House Energy and Commerce Committee. He and Rep. Diana DeGette, D-Colo., are chief authors of the bill.

The Obama administration has given the measure mixed reviews but has not threatened a veto. The Senate has yet to write its version of the legislation.

Defenders of the current system said the Food and Drug Administration, which regulates drugs and medical devices, already has an efficient approval process. Public Citizen, a consumer group, said the bill would trade increased federal research for “perks to the pharmaceutical and medical device industries” and called it “an assault on patient safety and science.”

The House bill would increase spending for the National Institutes of Health, which finances much of the country’s biomedical research, by $8.75 billion over the next five years. FDA would get an additional $550 million over that period.

The new spending would be paid for, mostly by selling $7 billion worth of oil from the Strategic Petroleum Reserve, the government’s emergency oil stockpile. Another $2.5 billion would come from trimming federal Medicaid reimbursements to states.

Conservatives were unhappy because the NIH and FDA would get their additional research funds automatically and because that money would be on top of — not part of — the amounts Congress spends annually on domestic programs.

“If you want a cure, go to the doctor, but if you want to clean up the U.S. economy, please consult an economist or two,” said Rep. Dave Brat, R-Va., a former economics professor who defeated former House Majority Leader Eric Cantor in a Republican primary last year.

By 281-141, the House rejected an amendment by Brat under which the research money would not be guaranteed. Republican leaders urged their colleagues to vote it down. Cantor, no longer in Congress, was among those urging lawmakers to support the original bill.

The abortion issue came up as Republicans sought to extend existing prohibitions on abortion funding to the legislation. Rep. Barbara Lee, D-Calif., called that “outrageous” and offered an amendment to undo the provision, but it was defeated easily. Democrats indicated they would not oppose the underlying bill over the issue given that the abortion funding restrictions already are in place in federal law.

Other provisions would speed how many drugs and devices reach consumers, such as letting regulators approve some medical equipment with shorter studies using fewer people. New uses of existing drugs could be based partly on case studies and other processes that are less rigorous than traditional clinical trials.

In a boon for pharmaceutical companies, the bill would give producers of existing drugs an extra six months of protection from competition if their drug is approved for use against rare diseases. There would be a streamlined process for approving new antibiotics for patients with resistant infections.

In a letter, the White House embraced the measure’s added research funds and efforts to accelerate drug development, but it criticized its extension of competition-free periods for some drugs and said some therapies would be available before their safety was proven.

AP Health Writer Matthew Perrone contributed to this report.


Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox.

We don’t spam! Read our privacy policy for more info.

Latest News

Gov. Greg Abbott endorses Drew Springer over Shelley Luther in Texas Senate special election runoff

Gov. Greg Abbott on Tuesday endorsed state Rep. Drew Springer, R-Muenster, in his bid to join the Texas Senate, charging into a heated intraparty...

Texas must boost coronavirus control efforts amid “full resurgence” of infections, White House report says

Texas must ramp up efforts to slow the spread of the coronavirus as the state experiences a “full resurgence” of COVID-19 infections, according to...

Mayor Price announces COVID recovery as cases surge in Texas

Fort Worth Mayor Betsy Price announced that she and her husband, Tom, have both recovered from COVID-19 on Monday, Nov. 30. “I am pleased to...

Q&A with Jaime Cobb/James L. West Center Vice President of Caregiver & Community Education

FWBP: Now that visiting restrictions are changing in long-term care, what do family members need to know? Jaime Cobb: Long-term care is still learning what...

COVID hospitalizations shut down bars in Texas county

By JUAN A. LOZANO Associated PressHOUSTON (AP) — A Central Texas county has closed its bars after area hospitalizations for COVID-19 exceeded a state...